Maxx Capece and Distinguished Professor Raj Dave
NJIT doctoral student Maxx Capece was awarded one of three, $2,000 first place prizes in a competition sponsored by the Catalent Institute. His winning submission entitled, “Modified Release of Dry-Polymer Coated Active Pharmaceutical Ingredients,” provided a review of applications of dry-polymer control release drug delivery technologies on the particulate scale. Winners of this global academic competition were chosen from leading U.S. and European universities with graduate programs in pharmaceutical science including Rutgers University, St. John’s University, University of North Carolina at Chapel Hill Purdue, and Heinrich Heine University of Düsseldorf, Germany.Capece’s entry showcased insights on enabling a broader range of controlled release application to dose forms such as film strips, solid oral dispersible tablets and liquid oral suspensions.
“We congratulate Maxx on winning this prestigious award, which recognizes ground-breaking approaches to drug development and pharmaceutical research,” said NJIT Distinguished Professor Raj Dave, who has also been the program advisor. “NJIT was honored to participate in this program, which offered students a valuable opportunity to compete with some of the world’s foremost scientific talent at the graduate level.” Competition winners will also receive a complimentary, one-year membership to the American Association of Pharmaceutical Scientists.
“Partnering with leading academic centers throughout the world is an important part of our mission at the Institute,” said Terry Robinson, executive director of the Catalent Applied Drug Delivery Institute. “Research and development collaborations with academic institutions foster innovation in applied drug delivery technology which can result in better treatments and improved patient care. The Institute is grateful to the participating universities for encouraging their students to pursue this wonderful opportunity.”
The Catalent Applied Drug Delivery Institute serves as a link between industry and academia by providing guidance, counsel and resources on major issues pertaining to drug development, formulation and delivery. The Institute promotes innovation, knowledge-sharing and collaboration to enhance understanding and accelerate adoption of applied drug delivery technologies as a means to develop better treatments and improve patient care. An initiative of Catalent Pharma Solutions, the Institute is pursuing a multi-tiered approach of seed funding, strategic counsel and educational programs to advance the adoption of emerging technologies. For more information, visit www.drugdeliveryinstitute.com.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across five continents, and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.